Global study by Novartis and European Migraine and Headache Alliance reveals 60% of employed people with severe migraine miss, on average, a week of work per month

Novartis and the European Migraine and Headache Alliance (EMHA) announced initial findings from the largest global migraine patient study to date, involving over 11,000 people from 31 countries. Migraine is a neurological disease which can vary in severity with symptoms ranging from head pain, nausea, vomiting to sensitivity to light.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news